HDAC4 and urothelial carcinoma: CBX7 could inhibit the invasion ability of BCa 26, and Kaletsch A et al. identified that HDAC4 served as a tumor promoting factor, and Histone deacetylase inhibitor (HDACi) was considered to be a promising anti-cancer drug, which could be employed for the treatment of urothelial carcinoma (UC) 43.